Hyperoside (Synonyms: Hyperoside, NSC 407304, Quercetin-3-O-galactoside) |
Catalog No.GC38430
One-Click Copy Product Info
|
Hyperoside is a NF-κB inhibitor, found from Hypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activitie.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 482-36-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Hyperoside is a NF-κB inhibitor, found from Hypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activitie[1][2].
Hyperoside (0.5, 1, 2mM; 24, 48h) dose-dependently inhibited the phosphorylation of Akt, mTOR, p70S6K and 4E-BP1, but increased the phosphorylation of ERK1/2 in A549 cells[1]. With increasing concentrations of Hyperoside (25, 50, 100mM) treatment, the phosphorylation levels of IκBα and p65 in MCF-7 and 4T1 cells decreased[2]. Hyperoside (0-300µM) inhibited cell proliferation in U2OS and MG63 cells in a dose-dependent manner at 72h, with IC50 values of 223.5 and 239.0µM, respectively[3].
Hyperoside (50mg/kg; ip; every two days for 18 days) inhibited the activation of the NF-κB pathway and reduced translocation of p-p65 in the nucleus by reducing ROS production in 4T1 cells. Inhibition of NF-κB down-regulates the transcription of anti-apoptotic genes, such as Bcl-2 and XIAP, but it also induced the accumulation of Bax, which leads to mitochondrial dysfunction and leads to apoptosis by activating caspase-3[2]. For ovariectomized (OVX) mice, Hyperoside (20, 40, 80mg/kg) was effective in preventing osteoporosis by increasing bone mineral density, restoring trabecular bone micro-architecture, and enhancing bone strength[4]. In the bleomycin-induced pulmonary fibrosis model, Hyperoside (50mg/kg; 14 days) treatment can improve the pathological changes of fibrosis and collagen deposition in the lung tissue of mice with bleomycin-induced pulmonary fibrosis. Hyperoside treatment can also reduce the content of MDA, TNF-α and IL-6, and increase the activity of SOD[5].
References:
[1]. Fu T, Wang L, Jin X, et al. Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro[J]. Acta Pharmacologica Sinica, 2016, 37(4): 505-518.
[2]. Qiu J, Zhang T, Zhu X, et al. Hyperoside induces breast cancer cells apoptosis via ROS-mediated NF-κB signaling pathway[J]. International Journal of Molecular Sciences, 2019, 21(1): 131.
[3].Zhang N, Ying M D, Wu Y P, et al. Hyperoside, a flavonoid compound, inhibits proliferation and stimulates osteogenic differentiation of human osteosarcoma cells[J]. PloS one, 2014, 9(7): e98973.
[4]. Chen Y, Dai F, He Y, et al. Beneficial effects of hyperoside on bone metabolism in ovariectomized mice[J]. Biomedicine & Pharmacotherapy, 2018, 107: 1175-1182.
[5]. Huang J, Tong X, Zhang L, et al. Hyperoside attenuates bleomycin-induced pulmonary fibrosis development in mice[J]. Frontiers in Pharmacology, 2020, 11: 550955.
| Cell experiment [1]: | |
Cell lines | MCF-7 cells and 4T1 cells |
Preparation Method | MCF-7 cells and 4T1 cells were treated with different concentrations of Hyperoside (25, 50 or 100μM) for 24 h. |
Reaction Conditions | 25, 50, 100mM; 12h |
Applications | With increasing concentrations of Hyperoside treatment, the phosphorylation levels of IκBα and p65 in MCF-7 and 4T1 cells decreased. |
| Animal experiment [1]: | |
Animal models | Breast cancer modle |
Preparation Method | 4T1 cells were harvested and suspended in 100μL PBS. Then injected those cells into the fourth breast pad of the mice. Mice were randomized into three groups after rearing for 12 days, and the following administrations were executed: Hyperoside (50mg/kg; ip; every two days for 18 days), ROS scavenger (100mg/kg; ip; every two days for 18 days), or saline as the control group. |
Dosage form | 50mg/kg; ip; every two days for 18 days |
Applications | Hyperoside inhibited the activation of the NF-κB pathway and reduced translocation of p-p65 in the nucleus by reducing ROS production in 4T1 cells. Inhibition of NF-κB down-regulates the transcription of anti-apoptotic genes, such as Bcl-2 and XIAP, but it also induced the accumulation of Bax, which leads to mitochondrial dysfunction and leads to apoptosis by activating caspase-3. |
References: [1]. Qiu J, Zhang T, Zhu X, et al. Hyperoside induces breast cancer cells apoptosis via ROS-mediated NF-κB signaling pathway[J]. International Journal of Molecular Sciences, 2019, 21(1): 131. | |
| Cas No. | 482-36-0 | SDF | |
| Synonyms | Hyperoside, NSC 407304, Quercetin-3-O-galactoside | ||
| Canonical SMILES | OC1=CC(O)=C(C(C(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)=C(C3=CC=C(O)C(O)=C3)O4)=O)C4=C1 | ||
| Formula | C21H20O12 | M.Wt | 464.38 |
| Solubility | DMSO: 250 mg/mL (538.35 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1534 mL | 10.767 mL | 21.5341 mL |
| 5 mM | 430.7 μL | 2.1534 mL | 4.3068 mL |
| 10 mM | 215.3 μL | 1.0767 mL | 2.1534 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)